La Jolla Labs Announces Leadership Transition as Company Evolves from Technology to Therapeutics
​​
San Diego, CA –-02/01/2025– La Jolla Labs, Inc., today announced a strategic leadership transition as it advances from a technology-driven company to an RNA therapeutics-focused organization.
​
La Jolla Labs Co-founder Tamar Grossman, Ph.D., formerly Global Head of Gene Therapy, RNA, and Delivery at Johnson & Johnson, will assume the position of Chief Executive Officer. Dr. Grossman brings extensive experience in RNA therapeutics and drug delivery, positioning the company for its next phase of growth in developing transformative treatments.
Co-founder Jeff Milton, the outgoing Chief Executive Officer, will take on the role of Chief Technology Officer, where he will continue to drive scientific innovation and platform development.​
​
In addition to founding La Jolla Labs, Jeff and Tamar have worked together in RNA therapeutics for over a decade, including time at Ionis Pharmaceuticals and Arcturus Therapeutics. Their continued collaboration reflects a shared commitment to delivering life-changing therapies to patients with rare and underserved diseases.
“This transition marks an exciting new chapter for La Jolla Labs,” said Jeff. “With Tamar’s leadership and deep expertise in RNA and drug development, we are well-positioned to translate our cutting-edge technology into groundbreaking therapeutics.”
​​
“La Jolla Labs is entering a pivotal stage, and I am honored to lead the company as we evolve toward developing transformative therapeutics,” said Dr. Grossman. “Jeff and I have shared a vision for RNA-based innovation for many years where Jeff delivered tools and technology that enabled my team to develop therapeutics.”
La Jolla Labs remains committed to developing RNA-based technologies for novel therapeutics and address critical unmet medical needs.
​
​
​
For media inquiries, please contact:
Allison Brown
La Jolla Labs, Inc.
allisonmarie@lajollalabs.com
858 692 7000
About La Jolla Labs
La Jolla Labs, Inc. is a biotechnology company dedicated to advancing RNA-based therapeutics to address rare and complex diseases. With expertise in RNA engineering, delivery, and precision medicine, the company is committed to translating cutting-edge technology into life-changing treatments for patients worldwide.